These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 5041485)

  • 1. The mode of action of -methyldopa.
    Day MD; Roach AG; Whiting RL
    Br J Pharmacol; 1972 May; 45(1):168P-169P. PubMed ID: 5041485
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inhibitors of catecholamine biosynthesis (review of the literature)].
    Frantsuzova SB
    Farmakol Toksikol; 1973; 36(5):624-8. PubMed ID: 4150865
    [No Abstract]   [Full Text] [Related]  

  • 3. [Relationship between the antihypertensive activity of methyldopa and the appearance of its metabolites in the heart and brain of the hypertensive rat].
    Cohen Y; Wepierre J; Jacquot C; Rapin J
    Arch Int Pharmacodyn Ther; 1974 Feb; 207(2):348-60. PubMed ID: 4827419
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of different dopa decarboxylase inhibitors on the hypotensive response to alpha-methyldopa in rats.
    Henning M
    Br J Pharmacol; 1968 Sep; 34(1):233P-234P. PubMed ID: 5676035
    [No Abstract]   [Full Text] [Related]  

  • 5. The mechanism of the antihypertensive action of -methyldopa in hypertensive rats.
    Day MD; Roach AG; Whiting RL
    Eur J Pharmacol; 1973 Mar; 21(3):271-80. PubMed ID: 4196583
    [No Abstract]   [Full Text] [Related]  

  • 6. Urinary excretion of noradrenaline after treatment with alpha-methyldopa: inhibition by a central nervous mechanism.
    Andén NE; Henning M
    Acta Physiol Scand; 1974 Jan; 90(1):69-72. PubMed ID: 4814544
    [No Abstract]   [Full Text] [Related]  

  • 7. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of dopa decarboxylation by RO4-4602, MK 485 and MK 486 in human liver homogenates.
    Vogel WH; Mahoney K; Hare TA
    Arch Int Pharmacodyn Ther; 1972; 198(1):85-93. PubMed ID: 4538242
    [No Abstract]   [Full Text] [Related]  

  • 9. [Role of dopamine and noradrenaline in altering direct cortical response under the action of fenamin? phenamine?].
    Il'iuchenok RIu; Martynov NN
    Farmakol Toksikol; 1974; 37(6):655-8. PubMed ID: 4464087
    [No Abstract]   [Full Text] [Related]  

  • 10. [Methyldopa and levodopa].
    Chang CP
    Zhonghua Yi Xue Za Zhi; 1974; 7():439-41. PubMed ID: 4211508
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction of aromatic L-amino acid decarboxylase protein in rats after chronic administration of alpha-methyldopa.
    Culvenor AJ; Jarrott B
    Mol Pharmacol; 1979 Jan; 15(1):86-98. PubMed ID: 106235
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of the decarboxylase inhibitor benserazide on the antihypertensive effect and metabolism of alpha-methyldopa in patients with essential hypertension.
    Planz G; Gierlichs HW; Hawlina A; Planz R; Stephany W; Rahn KH
    Eur J Clin Pharmacol; 1977 Dec; 12(4):241-5. PubMed ID: 338308
    [No Abstract]   [Full Text] [Related]  

  • 13. Aggression in rats treated with dopa and 6-hydroxydopamine.
    Thoa NB; Eichelman B; Ng KY
    J Pharm Pharmacol; 1972 Apr; 24(4):337-8. PubMed ID: 4402848
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of disulfiram on the restoration of the response to tyramine by dopamine and alpha-methyl-dopa in the reserpine-treated cat.
    Musacchio JM; Bhagat B; Jackson CJ; Kopin IJ
    J Pharmacol Exp Ther; 1966 May; 152(2):293-7. PubMed ID: 5944371
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradrenaline.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1971 Jun; 23(6):407-11. PubMed ID: 4397178
    [No Abstract]   [Full Text] [Related]  

  • 16. [Research on the inhibitory action of several salicylic chalcones on the aromatic L-aminoacid-decarboxylase].
    Lesieur-Demarquilly I; Mizon J; Osteux R
    Ann Pharm Fr; 1973 Nov; 31(11):705-8. PubMed ID: 4794659
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for a centrally mediated hypotensive effect of L-dopa in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Mar; 22(3):241-3. PubMed ID: 4399501
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemistry and pharmacology of methyldopa and some related structures.
    Stone CA; Porter CC
    Adv Drug Res; 1967; 4():71-93. PubMed ID: 4902343
    [No Abstract]   [Full Text] [Related]  

  • 19. [Endogenous 3-O-methyldopa in man: normal level and effect of an inhibitor of aromatic amino-acid decarboxylase (Benserazid) (author's transl)].
    Geissbühler F; Raffin Y; Combépine C; Streiff U; Hovaguimian T
    J Clin Chem Clin Biochem; 1978 Jun; 16(6):355-8. PubMed ID: 670902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. POTENT DECARBOXYLASE INHIBITORS. ANALOGS OF METHYLDOPA.
    SLETZINGER M; CHEMERDA JM; BOLLINGER FW
    J Med Chem; 1963 Mar; 6():101-3. PubMed ID: 14188777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.